1. Antiproliferation activities of NK4 on multiple myeloma
   Wenzhong Que et al, 2018, Experimental and Therapeutic Medicine CrossRef
2. Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance
   Jose J. G. Marin et al, 2021, Cancers CrossRef
3. Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway
   William H. Gmeiner et al, 2015, Leukemia Research CrossRef
4. Current and novel therapeutic opportunities for systemic therapy in biliary cancer
   José J. G. Marin et al, 2020, British Journal of Cancer CrossRef
5. Cholangiocarcinoma 2020: the next horizon in mechanisms and management
   Jesus M. Banales et al, 2020, Nature Reviews Gastroenterology & Hepatology CrossRef
6. Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?
   Christian Mayr et al, 2022, Expert Opinion on Investigational Drugs CrossRef
7. Qingjie Fuzheng granules inhibit colorectal cancer cell growth by the PI3K/AKT and ERK pathways
   Hong Yang et al, 2019, World Journal of Gastrointestinal Oncology CrossRef
8. SP/NK‐1R promotes gallbladder cancer cell proliferation and migration
   Xue‐Ting Deng et al, 2019, Journal of Cellular and Molecular Medicine CrossRef
9. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
   Jesus M. Banales et al, 2016, Nature Reviews Gastroenterology & Hepatology CrossRef
10. MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen
    Richard E. Kast et al, 2022, Cancers CrossRef